Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Study to Evaluate Safety, Tolerability, and Pharmacodynamic Effect After Single Administration of PER-001 Intravitreal Implant in Participants With Open-Angle Glaucoma

Next Previous
Search
Trial Profile

A Phase 1/2a Study to Evaluate Safety, Tolerability, and Pharmacodynamic Effect After Single Administration of PER-001 Intravitreal Implant in Participants With Open-Angle Glaucoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PER 001 (Primary)
  • Indications Open-angle glaucoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Perfuse Therapeutics

Most Recent Events

  • 06 May 2025 According to a Perfuse Therapeutics media release, positive 24-week results from this study were presented at the Association for Research in Vision and Ophthalmology (ARVO) Meeting.
  • 06 May 2025 Results presented in a Perfuse Therapeutics media release.
  • 06 May 2025 According to a Perfuse Therapeutics media release, Steven Mansberger was an investigator of this study.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top